Beta Blockers —
Cardioselective vs Non-Selective

Metoprolol succinate is the most prescribed beta blocker in the United States and arguably the most clinically important agent in this drug class. The succinate salt form uses an extended-release matrix that delivers metoprolol over 24 hours — a pharmacokinetic advantage that translates directly into clinical outcomes. Once-daily dosing improves adherence and, critically, produces steadier blood levels than the peaks and troughs of twice-daily metoprolol tartrate.

The MERIT-HF trial (1999) established metoprolol succinate as a cornerstone of heart failure management: the trial was stopped early because patients receiving it showed a 34% reduction in all-cause mortality compared to placebo. This survival benefit in heart failure specifically requires the extended-release succinate formulation — the tartrate form was not studied in MERIT-HF and the two are not interchangeable for this indication. Metoprolol succinate is also used for hypertension, chronic stable angina, and post-myocardial infarction cardioprotection.

Available in 25mg, 50mg, 100mg, and 200mg extended-release tablets. Widely available as generic metoprolol succinate. The tablet can be split but should not be crushed, as this destroys the extended-release mechanism.

Metoprolol tartrate is the immediate-release salt formulation of metoprolol, typically dosed twice daily due to its short 3–7 hour half-life. It is the same molecule as metoprolol succinate — only the salt and release mechanism differ, but these differences have real clinical consequences. Blood levels with tartrate fluctuate more between doses: higher peaks shortly after each dose, lower troughs before the next. This variability is less desirable in the chronic management of heart failure, where succinate is strongly preferred.

Tartrate is not without its place. It is less expensive than succinate, which matters for patients managing cost. In acute hospital settings, intravenous metoprolol tartrate is used for rate control in atrial fibrillation, management of acute MI, and hypertensive urgency — situations where IV dosing with rapid titration is needed. In the emergency department and intensive care unit, the IV form is practical and effective. Orally, tartrate remains appropriate for hypertension and angina in patients who cannot afford succinate or who do not have heart failure as an indication.

Atenolol stands apart from metoprolol in a clinically meaningful way: it is hydrophilic (water-soluble), which means it does not readily cross the blood-brain barrier. The practical consequence is that atenolol causes substantially less CNS-mediated side effects — fatigue, sleep disturbance, vivid dreams, and the mood changes sometimes attributed to lipophilic beta blockers are less common with atenolol. For patients who find metoprolol difficult to tolerate neurologically, atenolol is often a well-tolerated alternative.

Atenolol is renally cleared — it is not significantly metabolized by the liver. This has two implications. First, hepatic CYP2D6 metabolism (which affects metoprolol pharmacokinetics in poor metabolizers) is irrelevant to atenolol's behavior. Second, dose adjustment is essential in renal impairment, as the drug accumulates when the kidneys cannot excrete it efficiently. Once-daily dosing is supported by its 6–9 hour half-life.

For years atenolol was among the most prescribed antihypertensives worldwide. Its position has softened somewhat following the ASCOT trial and meta-analyses suggesting it may be less effective than other agents at reducing stroke risk, despite equivalent blood pressure lowering — though it remains widely used and guideline-supported for hypertension and angina.

Bisoprolol holds a distinctive position in the beta blocker class: it has the highest degree of cardioselectivity of any commercially available agent, with a beta-1 to beta-2 selectivity ratio substantially greater than metoprolol or atenolol. In practical terms, this means bisoprolol has the least impact on airway smooth muscle at therapeutic doses — making it the preferred cardioselective agent when a beta blocker is genuinely needed in a patient with reactive airway disease (though caution and specialist guidance remain appropriate).

The CIBIS-II trial demonstrated a 34% reduction in all-cause mortality in patients with heart failure with reduced ejection fraction (HFrEF) treated with bisoprolol — parallel evidence to MERIT-HF with metoprolol succinate, establishing bisoprolol as a proven heart failure agent alongside carvedilol and metoprolol succinate. European heart failure guidelines favor bisoprolol, carvedilol, or metoprolol succinate as the three evidence-based beta blockers for HFrEF.

Bisoprolol is eliminated roughly equally by renal and hepatic pathways (dual clearance), which gives it predictable pharmacokinetics in a wide range of patients with mild-to-moderate organ impairment — neither pathway alone is rate-limiting. Once-daily dosing. Available in 5mg and 10mg tablets generically.

Nebivolol is the newest beta blocker approved in the United States and has a pharmacological property unique among this class: in addition to beta-1 blockade, it stimulates endothelial production of nitric oxide (NO) — a potent vasodilator. This dual mechanism (beta-1 blockade slows the heart; NO-mediated vasodilation reduces peripheral resistance) lowers blood pressure through two complementary pathways. The vasodilation also partially counteracts the peripheral vasoconstriction that other beta blockers can cause.

The NO-releasing property has a clinically meaningful consequence for erectile function. Erectile dysfunction is a well-recognized side effect of beta blockers in general — reduced cardiac output and peripheral vasoconstriction both impair penile blood flow. Nebivolol's vasodilating mechanism actively works against this, and clinical data show substantially lower rates of sexual dysfunction with nebivolol compared to atenolol, metoprolol, and other agents. For sexually active men in whom beta blocker-related erectile dysfunction is a concern, nebivolol is the preferred option and may even improve erectile function compared to baseline.

Available in 2.5mg, 5mg, 10mg, and 20mg tablets. FDA approved for hypertension; sometimes used off-label in heart failure. Metabolized via CYP2D6 — poor metabolizers will have higher exposures.